Sandro Pasquali, MD, PhD (he/him/his)

Clinician Scientist
Sarcoma Service, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Italy

I am a clinical scientist and surgical oncologist working at the Molecular Pharmacology Unit and the Sarcoma Service of the Fondazione IRCCS Istituto Nazionale dei Tumori in Milan, Italy. Our translational research focuses on the identification of new therapeutic targets, the study of modifiers of tumor response, with a special emphasis on mechanisms of resistance to therapeutic options, as well as the exploration of prognostic and predictive markers for soft tissue sarcomas. To achieve these goals, we employ molecular profiling of sarcoma samples treated at our sarcoma units at INT and utilize a comprehensive collection of patient-derived models representing various sarcoma histologies. Additionally, we are interested in investigating changes to the sarcoma immune microenvironment induced by neoadjuvant chemotherapy.

Poster(s):

• (P 109) INTENSE PRECLINICAL ACTIVITY BY B7H3-SPECIFIC CAR.CIK LYMPHOCYTES AGAINST EPITHELIOID SARCOMA

• (P 126) CURRENT PRACTICE IN SPERMATIC CORD SARCOMA: ONCOLOGICAL TIMELINES AND OUTCOMES ACCORDING TO INITIAL RESECTIONS PERFORMED AT A LOCAL HOSPITAL VERSUS EARLY PATIENT REFERRAL TO A TERTIARY CENTRE.

• (P 272) A COMPARATIVE ASSESSMENT OF SELINEXOR WITH TRABECTEDIN OR LURBINECTEDIN IN PATIENT-DERIVED XENOGRAFTS (PDX) OF DEDIFFERENTIATED LIPOSARCOMA (DDLPS)

• (P 273) COMPARISON OF A PATIENT-DERIVED XENOGRAFTS (PDX) OF MYXOID PLEOMORPHIC LIPOSARCOMA (MPL) AND PLEOMORPHIC LIPOSARCOMA (PL) HIGHLIGHTS THE EFFECTIVENESS OF ERIBULIN IN A PDX OF MPL

• (P 378) MULTIOMICS PROFILING OF EPITHELIOID SARCOMA UNVEILS EPIGENETIC CIRCUITRIES THAT UNDERLIE THE PATHOBIOLOGY OF PROXIMAL AND CLASSIC SUBTYPES: RESULTS FROM THE ISG EPISOBS OBSERVATIONAL STUDY

• (P 410) PROTEOMICS ANALYSIS IDENTIFIES A SIGNATURE THAT IMPROVES PROGNOSTIC RISK STRATIFICATION OF THE SARCULATOR NOMOGRAM IN PATIENTS WITH SOFT TISSUE SARCOMAS OF THE EXTREMITIES AND TRUNK WALL